Skip to main content
. Author manuscript; available in PMC: 2011 Jun 1.
Published in final edited form as: J Immunol. 2010 May 5;184(11):6209–6222. doi: 10.4049/jimmunol.1000231

FIGURE 1. Recognition of HMBPP by Vγ2Vδ2 TCR transfectants expressing mutant Vγ2 chains.

FIGURE 1

J.RT3-T3.5 β− Jurkat cells were transfected with unmutated or mutated DG.SF13 TCR-γ cDNAs together with the unmutated DG.SF13 TCR-δ chain cDNA. After drug selection, anti-Cδ responsive transfectants were identified and stimulated with HMBPP in the presence of Va2 APCs and 2.5 ng/ml PMA. The anti-Cδ mAb (anti-TCRδ1) and HMBPP were added to the cultures stating at 2.15 µg/ml and 1000 nM, respectively, and serially diluted by half-log intervals. After 24 h, the culture supernatants were harvested and assayed for IL-2 activity using the IL-2-dependent cell line, HT2. Results from one transfectant are shown for each mutation and are representative of the results obtained with two to four other independently derived transfectants (Supplemental Fig. 1). Values shown are mean ± SEM of duplicate or triplicate samples. HMBPP reactivity was considered (++) if the maximum HMBPP response was >40% of the control anti-Cδ response, (+) if between 20–40% of the control response, and (−) if <10% of the control response.